New Antimicrobials Celebrated as a 'Pivotal Moment' in Combating Drug-Resistant Gonorrhoea
The first new treatments for gonorrhoea in many years are being described as a "major milestone" in the fight against drug-resistant strains of the pathogen, according to researchers.
An International Health Concern
The sexually transmitted infection are increasing worldwide, with figures suggesting over 82 million infections annually. Particularly high rates are observed in Africa and nations within the WHO's designated area, which spans from Mongolia and China to New Zealand. Within England, cases have reached a record high, while infection numbers across Europe in 2023 were triple the level compared to the rates from 2014.
“The clearance of novel therapies for gonorrhoea is an important and timely step in the context of growing infection rates, the spread of superbugs and the highly restricted available drugs currently available.”
Public health authorities are particularly alarmed about the increase in drug-resistant strains. The global health body has designated it as a "high-priority threat". Ongoing monitoring showed that resistance to key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.
Recent Drugs Receive Approval
One new antibiotic, also known as Nuzolvence, was approved by the US FDA in recent days for combating gonorrhoea. This infection can lead to major issues, including infertility. Scientists anticipate that targeted use of this new drug will help slow the spread of drug resistance.
Another new antibiotic, originating from the pharmaceutical company GlaxoSmithKline, gained clearance in close succession. This drug, which is employed against urinary tract infections, was shown in trials to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.
An Innovative Approach to Creation
This new treatment was the result of a unique collaborative effort for medication research. The charitable organization GARDP partnered with the pharmaceutical company Innoviva to bring it to fruition.
“This authorization marks a significant shift in the management of superbug gonorrhoea, which up to this point has been evolving faster than antibiotic development.”
Testing Outcomes and Global Access
According to results detailed in a prominent scientific publication, zoliflodacin cured over nine in ten of uncomplicated infections. This puts it on an comparable level with the current standard treatment, which involves a dual-drug approach. The research enrolled nearly 1,000 participants from multiple nations including the United States, Thailand, South Africa, and European nations.
Under the terms of its collaboration, the non-profit has the ability to license and sell the drug in a wide range of low-income and middle-income countries.
Medical professionals on the front lines have voiced optimism. Having a single-dose, oral treatment of this kind is hailed as a "game-changer" for gonorrhoea control. This is deemed essential to lessen the impact of the illness for people and to stop the proliferation of untreatable gonorrhoea globally.
